LAB CGRP is a natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated bronchodilatory, bronchoprotecting and anti-inflammatory properties in preclinical studies.
The objectives of the randomized, double blind, crossover phase II study were to investigate the protective efficacy of LAB CGRP on metacholine-induced bronchial hyper-responsiveness in adult patients with mild to moderate asthma, to compare this efficacy to salbutamol and placebo, and to evaluate the safety and tolerability of LAB CGRP in asthma patients.
The trial has enrolled a total of 12 patients. No serious adverse events have been reported in any of the patients dosed, and LAB International said that it expects to have results from the study available by the end of Q3 2006.
“The completion of patient enrollment in our first phase II trial for LAB CGRP brings us one step closer to demonstrating efficacy in adult asthma patients,” commented Dr Halvor Jaeger, CEO of LAB International. “If positively demonstrated, the bronchodilatory, anti-inflammatory and broncho-protective properties in patients would represent a significant benefit over the usual combination asthma therapies.”